

## **Ocimum Biosolutions Awarded US Patent for Molecular Toxicology**

**Gaithersburg, Md., US and Hyderabad, India – Monday, September 08, 2008** - Ocimum Biosolutions today announced the issuance of U.S. Patent No. US 7,415,358 B2 entitled 'Molecular toxicology modeling'. The patent describes elucidation of the global changes in gene expression and identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes can be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

**Anu Acharya, CEO, Ocimum Biosolutions,** said *"We have consistently been in the forefront of Genomics Innovation over many years and this patent reiterates our strong commitment to continue as a leader in this space."*

*"Ocimum Biosolutions (Gene Logic) will continue to innovate through areas like Genotyping, Gene Expression, PCR and other data validation approaches to bring the latest and most promising technologies to our pharmaceutical and biotech clients who have chosen us as their preferred partner in their discovery pursuit for more than a decade,"* added Anu Acharya.

### **About Ocimum Biosolutions:**

Ocimum Biosolutions (and its subsidiary company Gene Logic) is a leading integrated genomics company providing comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen Ocimum as their preferred outsourcing partner and utilize Ocimum's expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Gene Logic is a preferred outsourcing partner for providing integrated biorepository and genomic services for several global pharmaceutical companies. Gene Logic's global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world's largest commercial gene expression databases – BioExpress® and ToxExpress®, Gene Logic has expertise and capabilities that are unparalleled in the genomic services industry. Gene Logic provides multiple GLP-compliant platforms for gene expression and SNP genotyping data generation, full biorepository and genomic services support for the Genetic Alliance, which is an umbrella organization representing ~600 genetic advocacy groups. Besides providing the physical infrastructure for storing thousands of biological samples, Gene Logic provides services to assist sample accrual, IRB approvals, CRO training, sample collection, clinical data capture and management.

For more information, please visit [www.ocimumbio.com](http://www.ocimumbio.com) and [www.genelogic.com](http://www.genelogic.com)

### **Investor Contact:**

Chief Executive Officer  
Email: [ceo@ocimumbio.com](mailto:ceo@ocimumbio.com)

### **Customer & Media Contacts:**

Director – Marketing Alliances and Outreach, Ocimum Biosolutions  
Phone: +91 40-66627200  
Email: [pr@ocimumbio.com](mailto:pr@ocimumbio.com)